TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, and Helix Acquisition Corp. II (Nasdaq: HLXB) (“Helix”), a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management, announce that they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed “BridgeBio Oncology Therapeutics, Inc.” The combined company’s common stock is expected to be listed on Nasdaq under the ticker symbol BBOT.
Read the full article: BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company //
Source: https://www.businesswire.com/news/home/20250228624323/en/BridgeBio-Oncology-Therapeutics-BBOT-and-Helix-Acquisition-Corp.-II-Announce-Business-Combination-Agreement-to-Create-Publicly-Listed-Biotechnology-Company-Advancing-a-Pipeline-of-RAS-and-PI3K%CE%B1-Targeting-Medicines